| Literature DB >> 27594884 |
Riccarda Antiochia1, Paolo Bollella1, Gabriele Favero1, Franco Mazzei1.
Abstract
In the last decades, in vitro diagnostic devices (IVDDs) became a very important tool in medicine for an early and correct diagnosis, a proper screening of targeted population, and also assessing the efficiency of a specific therapy. In this review, the most recent developments regarding different configurations of surface plasmon resonance affinity biosensors modified by using several nanostructured materials for in vitro diagnostics are critically discussed. Both assembly and performances of the IVDDs tested in biological samples are reported and compared.Entities:
Year: 2016 PMID: 27594884 PMCID: PMC4995327 DOI: 10.1155/2016/2981931
Source DB: PubMed Journal: Int J Anal Chem ISSN: 1687-8760 Impact factor: 1.885
General classification of IVDD.
| Class | Individual risk | Public health risk | Examples |
|---|---|---|---|
| A |
|
| Selective/differential microbiological media, identification kits for cultured microorganisms |
| B |
|
| Hormones, vitamins, enzymes, metabolic markers |
| C |
|
| PSA or CEA screening |
| D |
|
| HIV, HCV, HBV, HTLV |
(∙) Low, (∙∙) moderate, and (∙∙∙) high.
Figure 1Scheme of bulk SPR with (a) nanoparticles incorporated onto the surface and (b) sandwich “assay” with nanoparticles amplification.
Figure 2Scheme of localized SPR by using metal nanoparticles as amplification system to improve the IVD devices thanks to the local electric field/surface plasmon interaction.
Figure 3Scheme of SPR imaging.
Main advantages and drawbacks about bulk SPR, localized SPR, and SPR imaging transduction in ABBs.
| Bulk SPR | Localized SPR | SPR imaging | |
|---|---|---|---|
|
| |||
| Label-free |
|
|
|
| Real-time monitoring |
|
|
|
| Sensitivity |
|
|
|
| Multidetection array | — |
|
|
| Reusability |
|
|
|
| Being easy to perform |
|
|
|
| Low sample/ligand volume required |
|
|
|
|
| |||
|
| |||
| Steric hindrance |
|
|
|
| Nonspecific adsorption of proteins |
|
|
|
| Low molecular weight detection |
|
|
|
(∙) Low, (∙∙) moderate, and (∙∙∙) high.
Main analytical performances of the reviewed biosensors based on bulk SPR.
| Analytes | Nanoparticles | Biotransducer | Detection limit (LOD) | IVDD class | References |
|---|---|---|---|---|---|
| PSA | AuNPs | Antibody | 0.1 ng mL−1 | C | Jung et al., 2009 [ |
| Ischemia modified albumin (IMA) | AuNPs | Antibody | 10 ng mL−1 | C | Li et al., 2013 [ |
| Progesterone | AuNPs | Antibody | 4.9 ng mL−1 | B | Yuan et al., 2007 [ |
| Insulin | AuNPs | Antibody | 0.5 pM | B | Frasconi et al., 2010 [ |
| Dopamine | AuNPs | Antibody | 2 nM | B | Matsui et al., 2005 [ |
| PSA | AuNPs | Antibody | 0.3 ng mL−1 | C | Uludag and Tothill, 2012 [ |
| PSA | AuNPs | Antibody | 300 fM | C | Choi et al., 2008 [ |
| Human cardiac myoglobin (cMb) | AuNPs | Antibody | 10 pM | B | Gnedenko et al., 2013 [ |
| CEA | Bio-AuNPs | Antibody | 0.1 ng mL−1 | C | Špringer and Homola, 2012 [ |
| CEA | AuNPs | Antibody | — | C | Špringer et al., 2014 [ |
| Necrosis factor alpha (TNF- | Gold nanorods (GNRs) | Antibody | 0.5 ng mL−1 | C | Law et al., 2011 [ |
| Thrombin (Thr) | AuNPs | Aptamer | 0.1 nM | B | Bai et al., 2013 [ |
| Brain natriuretic peptide (BNP) | Gold nanocubes (AuNCs) | Antibody/aptamer | — | C | Jang et al., 2014 [ |
| Thrombin (Thr) | Nanorods (NRs) and quasi-spherical nanoparticles (qsNPs) | Aptamer | 0.1 aM | B | Baek et al., 2014 [ |
| Thrombin (Thr) | AuNPs | Aptamer | 0.8 aM | B | He et al., 2014 [ |
| Thrombin (Thr) | Fe3O4 MNPs | Aptamer | 0.02 nM | B | Wang et al., 2011 [ |
|
| Core-shell Fe3O4-Au magnetic nanoparticles (MNPs) | Antibody | 0.65 ng mL−1 | C | Liang et al., 2012 [ |
| Staphylococcal Enterotoxin B (SEB) | Immunomagnetic beads (IMBs) | Antibody | 0.1 ng mL−1 | C | Soelberg et al., 2009 [ |
Main analytical performances of the reviewed biosensors based on localized SPR.
| Analytes | Nanoparticles | Biotransducer | Detection limit (LOD) | IVDD class | References |
|---|---|---|---|---|---|
| Amyloid-derived diffusible ligands (ADDL) | AuNPs | Antibody | — | C | Haes et al., 2005 [ |
| Avian influenza (A) | AuNPs | Antibody | 1 pg mL−1 | C | Park et al., 2012 [ |
| HIV-1 | AuNPs | Antibody | 0.2 pg mL−1 | D | Lee et al., 2013 [ |
| Extracellular adherence protein (EAP)/PSA | AuNPs | Antibody | 8 nM/1 pM | C | Chen et al., 2009 [ |
| Squamous cell carcinoma antigen (SCCa) | AuNPs | Antibody | 0.125 pM | C | Zhao et al., 2014 [ |
|
| AuNPs | Antibody | 41 zM | C | Aćimović et al., 2014 [ |
| Human epididymis secretory protein 4 (HE4) | AgNPs | Antibody | 4 pM | C | Yuan et al., 2012 [ |
| Microalbuminuria | AuNPs | Antibody | 1000 pg mL−1 | C | Lai et al., 2010 [ |
| p53 mutation | AgNPs | Antibody | 10 nM | C | Duan et al., 2012 [ |
| NADH | AuNPs | Antibody | — | B | Gu et al., 2015 [ |
Main analytical performances of the reviewed biosensors based on SPR imaging.
| Analytes | Nanoparticles | Biotransducer | Detection limit (LOD) | IVDD class | References |
|---|---|---|---|---|---|
| Nucleic Acid | AuNPs | Aptamer | 1 fM | C | Sendroiu et al., 2011 [ |
| miRNA | SiNPs | Aptamer | 100 fM | C | Zhou et al., 2011 [ |
| miRNA | AuNPs | Aptamer | 5 aM | C | Fang et al., 2006 [ |
| DNA | AuNPs | Aptamer | 10 aM | C | Gifford et al., 2010 [ |
| Single nucleotide polymorphisms (SNPs) | AuNPs | Aptamer | 1 pM | C | Li et al., 2006 [ |
| Single nucleotide polymorphisms (SNPs) | AuNPs | Aptamer | 32 nM | C | Sato et al., 2006 [ |
| DNA | AuNPs | Aptamer | 41 zM | C | D'Agata et al., 2010 [ |
| DNA | AuNPs | Aptamer | 0.02 aM | C | Yao et al., 2006 [ |
| miRNA | AuNPs | Aptamer | — | C | Wood et al., 2013 [ |
| IgG | AgNPs | Antibody | 1 nM | B | Paul et al., 2011 [ |